⚖️ Federal Rescheduling: On April 22, 2026, the U.S. DOJ issued a final order immediately moving state-licensed medical marijuana from Schedule I to Schedule III of the Controlled Substances Act. A broader DEA administrative hearing to consider rescheduling of all marijuana begins June 29, 2026.

Shay Aaron Gilmore – California Cannabis and Hemp Business Lawyer

Cannabis and Hemp Law Blog

While Rescheduling Unifies Some Federal Tax Treatment, California Cannabis and Hemp Keep Diverging Along the THC Line

Marijuana rescheduling now unifies some federal tax treatment, but California cannabis and hemp keep diverging along the THC line. This post walks operators and investors through what the shift means for entity choice, Section 280E, ownership disclosure, exits, and staying compliant — and why the cannabis-hemp divide is widening even as one federal tax answer emerges.

The April 22 Rescheduling Order: What We Know, What We Don’t, and What to Watch Before June 29

The April 22, 2026 rescheduling order moves state-licensed medical marijuana to Schedule III — but leaves adult-use cannabis in Schedule I, creates contested treaty-compliance mechanisms, and opens a June 27 DEA registration deadline that demands immediate attention from California dual A/M operators. Here is what we know, what remains genuinely uncertain, and what to watch before June 29.

Recent and Expected California Cannabis & Hemp Rulemaking to Govern the Licensed Supply Chains for Years to Come

California cannabis and hemp operators face five active or anticipated rulemakings in 2026 — covering multipack cannabis goods, pesticide residue testing, cultivation requirements, METRC track-and-trace reform, and AB 8 implementation. California cannabis attorney Shay Aaron Gilmore breaks down each DCC rulemaking proceeding, the AB 8 two-year countdown to hemp-DCC licensing integration, and why administrative law counsel delivers its highest value before any enforcement action begins.

California’s 2026 Cannabis Bills: All Active, All in the Assembly, and a Critical Deadline Approaching

Every active 2026 California cannabis bill affecting licensed dispensaries and retailers — including AB 2532’s beverage overhaul — is now sitting in the Assembly Appropriations Committee with a hard May 15 deadline. California cannabis attorney Shay Aaron Gilmore breaks down all of the bills, their current status, who’s sponsoring them, and what operators need to do before the window closes. Read the full legislative update at shaygilmorelaw.com.

Where the Law Meets the Ground: A Spring 2026 Field Report for California Cannabis Operators and Investors

California’s spring 2026 cannabis landscape is being shaped by ground-level events that demand immediate attention from operators and investors: nine Santa Barbara County licenses revoked over odor compliance failures, geopolitical fuel price shocks stress-testing distribution contracts across the state, a wave of M&A deals introducing new joint venture and earnout structures, and pricing data from Michigan and the East Coast confirming that California’s price compression is structural — not temporary. California cannabis attorney Shay Aaron Gilmore analyzes what it means for your business.

Physician-Furnished, Legally Frozen: How AB 8 Locks California Out of the Federal Hemp-CBD Medicare Benefit

California’s AB 8 bans detectable THC in hemp products sold outside licensed dispensaries — putting the state on a direct collision course with the new CMS Substance Access BEI, which allows physicians to furnish hemp-CBD products worth up to $500 annually to Medicare patients. Here’s what ACOs, hemp businesses, and healthcare providers need to know.